{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T09:04:01Z","timestamp":1746435841343,"version":"3.37.3"},"reference-count":22,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5,10]]},"DOI":"10.1182\/bloodadvances.2021006865","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T22:23:44Z","timestamp":1643408624000},"page":"2893-2896","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Rapid next-generation sequencing aids in diagnosis of transient abnormal myelopoiesis in a phenotypically normal newborn"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4753-5144","authenticated-orcid":false,"given":"Rahela","family":"Aziz-Bose","sequence":"first","affiliation":[{"name":"Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Harvard Medical School, Boston, MA;"},{"name":"Division of Hematology\/Oncology, Boston Children's Hospital, Boston, MA,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"Wachter","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Harvard Medical School, Boston, MA;"},{"name":"Division of Hematology\/Oncology, Boston Children's Hospital, Boston, MA,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1564-8531","authenticated-orcid":false,"given":"Roberto","family":"Chiarle","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA;"},{"name":"Department of Pathology, Boston Children\u2019s Hospital, Boston, MA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal I.","family":"Lindeman","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA;"},{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8699-2439","authenticated-orcid":false,"given":"Annette S.","family":"Kim","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA;"},{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara A.","family":"Degar","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Harvard Medical School, Boston, MA;"},{"name":"Division of Hematology\/Oncology, Boston Children's Hospital, Boston, MA,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Davies","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Harvard Medical School, Boston, MA;"},{"name":"Division of Hematology\/Oncology, Boston Children's Hospital, Boston, MA,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5336-0216","authenticated-orcid":false,"given":"Yana","family":"Pikman","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Harvard Medical School, Boston, MA;"},{"name":"Division of Hematology\/Oncology, Boston Children's Hospital, Boston, MA,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2022,5,6]]},"reference":[{"issue":"8","key":"2022050615304444800_B1","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1038\/s41375-020-0854-5","article-title":"Gain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome","volume":"34","author":"Laurent","year":"2020","journal-title":"Leukemia."},{"issue":"1","key":"2022050615304444800_B2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng955","article-title":"Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome","volume":"32","author":"Wechsler","year":"2002","journal-title":"Nat Genet."},{"issue":"8","key":"2022050615304444800_B3","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2003-02-0390","article-title":"Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome","volume":"102","author":"Xu","year":"2003","journal-title":"Blood."},{"issue":"1","key":"2022050615304444800_B4","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1038\/s41467-019-12726-0","article-title":"Functional profiling of single CRISPR\/Cas9-edited human long-term hematopoietic stem cells","volume":"10","author":"Wagenblast","year":"2019","journal-title":"Nat Commun"},{"issue":"4","key":"2022050615304444800_B5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrc2348","article-title":"GATA1-related leukaemias","volume":"8","author":"Shimizu","year":"2008","journal-title":"Nat Rev Cancer."},{"issue":"1","key":"2022050615304444800_B6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/iub.2197","article-title":"GATA1 and cooperating mutations in myeloid leukaemia of Down syndrome","volume":"72","author":"Garnett","year":"2020","journal-title":"IUBMB Life."},{"issue":"1","key":"2022050615304444800_B7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ajmg.a.36861","article-title":"Mosaicism for trisomy 21: a review","volume":"167A","author":"Papavassiliou","year":"2015","journal-title":"Am J Med Genet A."},{"issue":"6","key":"2022050615304444800_B8","first-page":"E52","article-title":"Transient abnormal myelopoeisis and mosaic Down syndrome in a phenotypically normal newborn","volume":"7","author":"Prudowsky","year":"2020","journal-title":"Children (Basel)."},{"issue":"12","key":"2022050615304444800_B9","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1007\/s00431-013-2163-8","article-title":"Transient leukemia in a newborn without Down syndrome: case report and review of the literature","volume":"173","author":"Rozen","year":"2014","journal-title":"Eur J Pediatr."},{"issue":"26","key":"2022050615304444800_B10","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1182\/blood-2011-04-350017","article-title":"Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children\u2019s Oncology Group Study A2971","volume":"118","author":"Gamis","year":"2011","journal-title":"Blood."},{"issue":"2","key":"2022050615304444800_B11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ccell.2019.06.007","article-title":"Mechanisms of progression of myeloid preleukemia to transformed myeloid leukemia in children with Down syndrome","volume":"36","author":"Labuhn","year":"2019","journal-title":"Cancer Cell."},{"issue":"1","key":"2022050615304444800_B12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2009.07789.x","article-title":"Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis","volume":"147","author":"Roy","year":"2009","journal-title":"Br\u00a0J Haematol."},{"issue":"7","key":"2022050615304444800_B13","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1182\/blood-2003-10-3383","article-title":"Natural history of GATA1 mutations in Down syndrome","volume":"103","author":"Ahmed","year":"2004","journal-title":"Blood."},{"issue":"1","key":"2022050615304444800_B14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/pbc.20161","article-title":"Tetrasomy 21 transient leukemia with a GATA1 mutation in a phenotypically normal trisomy 21 mosaic infant: case report and review of the literature","volume":"44","author":"Sandoval","year":"2005","journal-title":"Pediatr Blood Cancer."},{"issue":"5","key":"2022050615304444800_B15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11899-016-0338-x","article-title":"Transient abnormal myelopoiesis and AML in Down syndrome: an update","volume":"11","author":"Bhatnagar","year":"2016","journal-title":"Curr Hematol Malig Rep."},{"issue":"1","key":"2022050615304444800_B16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat Med."},{"key":"2022050615304444800_B17","first-page":"7813048","article-title":"Acute megakaryoblastic leukemia with Trisomy 21 and Tetrasomy 21 Clones in a phenotypically normal child with mosaic Trisomy 21","volume":"2020","author":"Won","year":"2020","journal-title":"Case Rep Pediatr."},{"issue":"3","key":"2022050615304444800_B18","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2002-11-3599","article-title":"Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21","volume":"102","author":"Rainis","year":"2003","journal-title":"Blood."},{"issue":"11","key":"2022050615304444800_B19","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/blood-2002-12-3904","article-title":"Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis","volume":"101","author":"Mundschau","year":"2003","journal-title":"Blood."},{"issue":"8","key":"2022050615304444800_B20","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1038\/s41375-021-01128-1","article-title":"Sensitive GATA1 mutation screening reliably identifies neonates with Down syndrome at risk for myeloid leukemia","volume":"35","author":"Goemans","year":"2021","journal-title":"Leukemia."},{"issue":"11","key":"2022050615304444800_B21","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1182\/blood-2003-01-0013","article-title":"GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome","volume":"101","author":"Hitzler","year":"2003","journal-title":"Blood."},{"issue":"2","key":"2022050615304444800_B22","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/bjh.15390","article-title":"Guidelines for the investigation and management of transient leukaemia of Down syndrome","volume":"182","author":"Tunstall","year":"2018","journal-title":"Br J Haematol."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/9\/2893\/1895188\/advancesadv2021006865.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/9\/2893\/1895188\/advancesadv2021006865.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T15:31:22Z","timestamp":1651851082000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/9\/2893\/483743\/Rapid-next-generation-sequencing-aids-in-diagnosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,6]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,5,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006865","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published":{"date-parts":[[2022,5,6]]}}}